Newegg Commerce Inc
Change company Symbol lookup
Select an option...
NEGG Newegg Commerce Inc
CHFI China Finance Inc
SU Suncor Energy Inc
CUBI Customers Bancorp Inc
SMIT Schmitt Industries Inc
BA Boeing Co
AMSWA American Software Inc
V Visa Inc
SVFB SVF Investment Corp 2
DMO Western Asset Mortgage Opportunity Fund Inc

Consumer Discretionary : Internet & Direct Marketing Retail | Small Cap Value
Company profile

Newegg Commerce, Inc. is a technology-focused e-commerce company in North America. The Company has developed an online marketplace that delivers value to consumers, brands, and sellers in the technology products sector. It operates business-to-consumer (B2C) platforms, business-to-business (B2B) operations, and other online platforms. Its B2C platform focuses on selling information technology (IT) products, through its platforms, namely Newegg.Com, Newegg.Ca, And Newegg Global. The Company’s B2B platform focuses on providing office and IT equipment, through its platform. Its platforms offer a suite of e-commerce solutions, including product listing, fulfillment, marketing, customer service and other value-added tools and services. The Company’s product categories offered through its platforms, such as computer system, components, electronics, gaming, networking and smart home, office solutions, software and services, automotive and industrial, and health and sports.

Closing Price
Day's Change
0.06 (3.06%)
B/A Size
Day's High
Day's Low

10-day average volume:

Moderna is the latest company to produce a promising RSV vaccine

12:30 pm ET January 18, 2023 (MarketWatch)

Jaimy Lee

GlaxoSmithKline and Pfizer are also developing RSV vaccines -- and the FDA is expected to decide in a few months whether to approve their shots

Moderna's disclosure this week that its respiratory syncytial virus vaccine prevented most infections in older adults in a clinical trial further sets the stage for a competitive new market ahead of next winter's cold season.

The company's stock (MRNA) gained 3.6% in trading on Wednesday, the day after Moderna said in a news release that its experimental RSV vaccine had an efficacy rate of 83.7% in adults 60 and older. The full data set is expected to be shared at an unnamed medical meeting in the future.

Moderna tested the vaccine candidate in a randomized, double-blind, placebo-controlled Phase 3 clinical trial that enrolled 37,000 older adults in 22 countries, including the U.S. No safety concerns were reported. The most common adverse events were pain at the injection site, fatigue, headache and muscle aches.

The company said it plans to submit the vaccine to the Food and Drug Administration for regulatory approval in the first half of this year. Wall Street expects approval in 2024.

There are currently no RSV vaccines for adults or children, but the attention brought to vaccine development, including messenger RNA technology, as a result of the COVID-19 pandemic revitalized interest in RSV vaccines in what could be a $5 billion market. Though RSV causes regular cold symptoms in most people, it's of particular concern when it comes to infants, who breathe exclusively through their noses, and older adults, who are at a higher risk of developing lung infections or pneumonia. Up to 10,000 adults die every year from RSV infections, according to the Centers for Disease Control and Prevention.

Now GlaxoSmithKline , Johnson & Johnson (JNJ), and Pfizer (PFE) -- in addition to Moderna -- have RSV vaccine candidates in late-stage clinical trials.

Three shots so far have produced data that indicates they can prevent infection in adults older than 60 years old. The FDA is expected to make a decision whether to approve the investigational RSV vaccines developed by GSK and Pfizer in May. J&J's shot is currently in a Phase 3 clinical trial.

Moderna may use its Priority Review voucher to speed up the review process for its RSV vaccine. That would mean the company gets to participate in the 2024 contracting decision, according to SVB Securities analyst Mani Foroohar, who on Tuesday raised Moderna's price target to $111 from $102 based on the new RSV data.

"This is a milestone for MRNA's pipeline beyond COVID in demonstrating the competitive efficacy of mRNA vaccines," UBS Securities analysts told investors.

Moderna's first and only approved therapy is Spikevax, its COVID-19 vaccine. The company's stock has gained 5.4% over the past year, while the broader S&P 500 is down 14.4%.

-Jaimy Lee


(END) Dow Jones Newswires

January 18, 2023 12:30 ET (17:30 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.